Combariza-Vallejo Juan F, Orduz-Rodriguez Rocío, Gomez-Lopera Natalia, Colmenares-Mejia Claudia C, Mejía-Casadiego Fabián A, Godoy-Corredor Marcela, Isaza-Ruget Mario Arturo
Hematology Service, Clinica Universitaria Colombia, Clinica Colsanitas, Grupo Keralty, Bogotá, Colombia.
Clinical and Pathology Laboratory, Clinica Colsanitas, Grupo Keralty, Bogotá, Colombia.
Hematol Oncol. 2025 May;43(3):e70085. doi: 10.1002/hon.70085.
Mantle cell lymphoma is a type of B-cell lymphoma with limited epidemiologic data in Latin America. The main objective was evaluating survival, in mantle cell lymphoma in Colombia and the influence of hematopoietic stem cell transplantation in the outcomes. In a retrospective cohort of new diagnostic Mantle Cell Lymphoma between 2010 and 2024, we identified main characteristics at diagnosis and the influence of MIPI score and ASCT. We followed patients until progression or death and compared progression-free survival and overall survival. We included 139 patients; the median age was 64 years. For patients classified as low risk according to the MIPI score, the 36-month OS rate was 79.7% (95% CI: 68%-93.5%). Intermediate risk 51.5% (95% CI: 38.2%-69.4%). And High-risk 40.4% (95% CI: 26.9%-59.5%) (p < 0.001). In the group that underwent ASCT, the 36-month OS rate was 75.2% (95% CI: 60.1%-94.6%), and in the non-transplanted group was 49% (95% CI: 39.5%-60.7%), HR 0.38 (95% CI; 019-0.74) (p = 0.002). High-risk patients and those who were not transplanted had the lowest survival compared to the other categories. These findings underscore the need for risk stratification, and effective treatment strategies, including the HSCT patient population in Colombia.
套细胞淋巴瘤是一种B细胞淋巴瘤，在拉丁美洲的流行病学数据有限。主要目的是评估哥伦比亚套细胞淋巴瘤的生存率以及造血干细胞移植对治疗结果的影响。在一项对2010年至2024年间新诊断的套细胞淋巴瘤患者的回顾性队列研究中，我们确定了诊断时的主要特征以及国际预后指数（MIPI）评分和自体造血干细胞移植（ASCT）的影响。我们对患者进行随访直至疾病进展或死亡，并比较无进展生存期和总生存期。我们纳入了139例患者；中位年龄为64岁。根据MIPI评分分类为低风险的患者，36个月总生存率为79.7%（95%置信区间：68%-93.5%）。中风险为51.5%（95%置信区间：38.2%-69.4%）。高风险为40.4%（95%置信区间：26.9%-59.5%）（p<0.001）。在接受ASCT的组中，36个月总生存率为75.2%（95%置信区间：60.1%-94.6%），未移植组为49%（95%置信区间：39.5%-60.7%），风险比（HR）为0.38（95%置信区间：0.19-0.74）（p=0.002）。与其他类别相比，高风险患者和未接受移植的患者生存率最低。这些发现强调了进行风险分层以及制定有效治疗策略的必要性，包括哥伦比亚的造血干细胞移植患者群体。
